Ophthalmology Times: July 1, 2021

Clinical trials show subretinal agents are safe, well tolerated by patients.

Focus on maximizing visual examination by combining methods of detection-based testing.

As soon as 2 weeks after treatment, changes occur to foveal layer.

Trifocal IOLs can, if implanted with caution, be suitable for patients with keratoconus.

Sustained findings over long term indicate no rebound of disease.

First step is ruling out ocular nystagmus, saccadic disorder.

Dual imaging may reduce costs, unnecessary referrals, telehealth study results show.

This research was a finalist in the 2020 Ophthalmology Times® Research Scholar Honoree Program.

Physician offers practical advice for the use of systems.

Although minimally invasive procedure gives hope, additional research is required.

Administration has minimal impact on patients’ perception of pain.

Ophthalmologists seek methods to control postoperative inflammation.

FDA approval of teprotumumab as therapeutic offers hope for patients.

Investigators find little difference between the options.